A recent study shows the impact of sarcopenia on patients with non-metastatic breast cancer.


Mark Pegram, MD, discusses the ongoing and planned clinical trials for abemaciclib and ribociclib in ER+ metastatic breast cancer, as well as the future implications for this class of agents in this patient population.
Mark Pegram, MD, discusses clinical data on the efficacy and safety of the FDA-approved CDK 4/6 inhibitor, palbociclib, in combination with letrozole in ER+ metastatic breast cancer.
Mark Pegram, MD, describes the rationale and mechanism for inhibiting this dysregulated pathway in estrogen receptor-positive metastatic breast cancer using selective CDK 4/6 inhibitors.
Genomic analysis revealed differences in the landscape of estrogen receptor-positive cancers when compared with ER+ primary tumors.


In some patients with estrogen receptor positive, human epidermal growth factor receptor 2 negative breast cancer, acquired HER2 mutations cause endocrine resistance.
Breast cancer prognostic tests have shown significant variation in their abilities to predict disease recurrence.
Women who receive MRI screening for breast cancer are more likely to receive invasive surgical biopsies to look for tumors compared with women who only receive screening mammograms.
A panel of 18 SNPs “substantially improves” breast cancer risk prediction and identification of women who may benefit most from preventive therapy or additional screening.

Research in Review

A bone metastasis model has been created that simulates interactions between metastatic breast cancer cells and bone cells to determine effectiveness of different treatments.
Adding palbociclib to fulvestrant prolongs progression-free survival compared with fulvestrant alone among pre- and post-menopausal women with HR-positive/HER2-negative metastatic breast cancer.
Using body composition metrics to determine dosage of anthracyclines-taxane based chemotherapy for patients with breast cancer can reduce treatment-related toxicity, according to a study published in Clinical Cancer Research.
Women with breast cancer are more likely to discontinue chemoprevention therapy if menopause-specific symptoms negatively impact their quality of life (QOL).
Subscribe to Breast Cancer